Toxins and Antivenoms of Latrodectus tredecimguttatus: Molecular Mechanisms, Antibody Development, and Evidence from Other Latrodectus Species
- 1The Faculty of Veterinary Medicine and Zooengineering, Kazakh National Agrarian Research University, Abay Avenue 8, Almaty 050010, Kazakhstan
- 2Research and Production Enterprise Antigen LTD, Karasai District, Abay Village, 4 Azerbayev Str., Almaty 040905, Kazakhstan
- 3School of Pharmacy, Asfendiyarov Kazakh National Medical University, Tole-bi 94, Almaty 050012, Kazakhstan
Abstract
Latrodectus tredecimguttatus envenomation causes latrodectism, a neurotoxic syndrome driven primarily by α-latrotoxin (α-LTX)-mediated dysregulation of neurotransmitter release. This review examines the development and therapeutic application of specific immunoglobulins against L. tredecimguttatus toxins, integrating toxin diversity, α-LTX mechanisms, antibody production, preclinical neutralization, and clinical use. Eggs and spiderlings also contain bioactive proteins, including Latroeggtoxin-I and Latroeggtoxin-IV, although their relevance to human envenomation and antivenom development remains uncertain. α-LTX acts through receptor engagement, membrane pore formation, Ca2+ influx, and receptor-mediated signaling, providing potential targets for antibody neutralization. Conventional antivenoms rely mainly on animal-derived polyclonal immunoglobulins, whereas phage display and recombinant engineering enable fully human monoclonal antibodies with defined specificity and high affinity. Preclinical studies demonstrate neutralization across cellular, electrophysiological, ex vivo, and in vivo models, but methodological heterogeneity and variable cross-species activity complicate efficacy comparisons. Recombinant human antibodies offer improved molecular definition, reproducibility, and engineering potential, although clinical efficacy remains unestablished. Future development should prioritize standardized neutralization assays, clinically relevant post-exposure models, systematic cross-neutralization studies, and recombinant antibody combinations to achieve broader toxin coverage and safer, more standardized, reproducible, and clinically applicable immunotherapy for L. tredecimguttatus envenomation.
Related
- Mathematical model for visual cortical development based on molecular mechanisms underlying the generation and elimination of dendritic spines
- Advances in the Functions and Molecular Mechanisms of SPL Transcription Factors in Plant Flower Development
- Proprioceptive sensory-driven mechanisms shape Clarke’s column development
- Trained immunity in cancer immunotherapy and vaccine development: mechanisms, evidence gaps, and translational opportunities
- The SPL8‐YAB3/TCP19 module integrates transcriptional and protein–protein regulatory mechanisms to orchestrate anther development in Arabidopsis
BibTeX
@article{rakhim2026toxins,
title = {{Toxins and Antivenoms of Latrodectus tredecimguttatus: Molecular Mechanisms, Antibody Development, and Evidence from Other Latrodectus Species}},
author = {Marziya Rakhim and Assima Abekova and Zhanserik Shynykul and Moldir Koilybayeva and Zhanat Batanova and Ernur Nurolda and Nurlan Akhmetsadykov},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209112},
url = {https://www.mdpi.com/1422-0067/27/20/9112},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Toxins and Antivenoms of Latrodectus tredecimguttatus: Molecular Mechanisms, Antibody Development, and Evidence from Other Latrodectus Species
AU - Marziya Rakhim
AU - Assima Abekova
AU - Zhanserik Shynykul
AU - Moldir Koilybayeva
AU - Zhanat Batanova
AU - Ernur Nurolda
AU - Nurlan Akhmetsadykov
PY - 2026
DA - 2026/10/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209112
UR - https://www.mdpi.com/1422-0067/27/20/9112
AB - Latrodectus tredecimguttatus envenomation causes latrodectism, a neurotoxic syndrome driven primarily by α-latrotoxin (α-LTX)-mediated dysregulation of neurotransmitter release. This review examines the development and therapeutic application of specific immunoglobulins against L. tredecimguttatus toxins, integrating toxin diversity, α-LTX mechanisms, antibody production, preclinical neutralization, and clinical use. Eggs and spiderlings also contain bioactive proteins, including Latroeggtoxin-I and Latroeggtoxin-IV, although their relevance to human envenomation and antivenom development remains uncertain. α-LTX acts through receptor engagement, membrane pore formation, Ca2+ influx, and receptor-mediated signaling, providing potential targets for antibody neutralization. Conventional antivenoms rely mainly on animal-derived polyclonal immunoglobulins, whereas phage display and recombinant engineering enable fully human monoclonal antibodies with defined specificity and high affinity. Preclinical studies demonstrate neutralization across cellular, electrophysiological, ex vivo, and in vivo models, but methodological heterogeneity and variable cross-species activity complicate efficacy comparisons. Recombinant human antibodies offer improved molecular definition, reproducibility, and engineering potential, although clinical efficacy remains unestablished. Future development should prioritize standardized neutralization assays, clinically relevant post-exposure models, systematic cross-neutralization studies, and recombinant antibody combinations to achieve broader toxin coverage and safer, more standardized, reproducible, and clinically applicable immunotherapy for L. tredecimguttatus envenomation.
SN - 1422-0067
ER -